search
Back to results

Safety and Efficacy of Empiric Levothyroxine (LT4) Dose Increase Versus Individualized LT4 Dose Increase in Hypothyroid Women During Pregnancy

Primary Purpose

Pregnancy Related, Thyroid

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
levothyroxine
Sponsored by
Medstar Health Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pregnancy Related focused on measuring Thyroid Stimulating Hormone

Eligibility Criteria

18 Years - 45 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Female between ages of 18-45 who takes thyroid hormone replacement medicine AND pregnant or plan to become pregnant in the near future.

Exclusion Criteria:

  • Males
  • Younger than 18 or older than 45 years old
  • More than 10 weeks pregnant at enrollment
  • Iodine deficient
  • Pregnant with more than one baby (i.e., twins, triplets, etc.)
  • NOT taking thyroid hormone medicine before becoming pregnant
  • Levels of thyroid hormone in blood have been too low or too high in the past 6 months
  • Treated with radioactive iodine in the past year.

Sites / Locations

  • Medstar Washington Hospital Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Adjustment in number of doses of thyroid hormone per week

Adjustment in micrograms per day of thyroid hormone

Arm Description

Patients in this group will increase pre-pregnancy thyroid hormone dose by 2 doses/week (extra dose on Wednesday and Saturday). Further dose adjustment are made every 2-4 weeks based on serum TSH, as shown below: TSH>10mIU/L, increase by 3 doses/week TSH 5.0-9.9mIU/L, increase by 2 doses/week TSH 2.0-4.9mIU/L, increase by 1 dose/week TSH 0.4-1.9mIU/L, no change TSH<0.4mIU/L, decrease by 1 dose/week TSH<0.1mIU/L, decrease by 2 doses/week Thyroid hormone dose will NOT be decreased due to TSH<0.4mIU/L during the 1st trimester unless patient also has elevated circulating T4 and/or T3 levels, indicate of true hyperthyroidism.

Patients in this group adjust thyroid hormone dose based on Visit 1 TSH and pre-pregnancy thyroid hormone dose. Further dose adjustments are made every 2-4 weeks based on serum TSH, as shown below: TSH>10mIU/L, increase dose by 50mcg/day if dose <125mcg/day or increase by 75mcg/day if dose >125mcg TSH 5.0-9.9mIU/L, increase dose by 25mcg/day if dose <125mcg/day or increase by 50mcg/day if dose >125mcg TSH 2.0-4.9mIU/L, increase dose by 12.5mcg/day if dose <125mcg/day or increase by 25mcg/day if dose >125mcg TSH 0.4-1.9mIU/L, no change TSH<0.4mIU/L, decrease dose by 12.5mcg/day if dose <125mcg/day or decrease by 25mcg/day if dose >125mcg/day TSH<0.1mIU/L, decrease dose by 25mcg/day if dose <125mcg/day or decrease by 50mcg/day if dose >125mcg/day Thyroid hormone dose will NOT be decreased due to TSH<0.4mIU/L during the 1st trimester unless patient also has elevated circulating T4 and/or T3 levels, indicate of true hyperthyroidism.

Outcomes

Primary Outcome Measures

% of TSH values within trimester-specific goal range per patient from study enrollment to delivery
% of TSH values within trimester-specific goal range according to study group

Secondary Outcome Measures

Mean number of LT4 dose adjustment
Mean number of LT4 dose adjustments needed per patient in each group
Mean number of LT4 dose adjustments by hypothyroidism etiology
Mean number of LT4 dose adjustments needed according to etiology of hypothyroidism in each group
% of TSH values at goal according to anti-thyroid antibody status
TSH values within trimester specific goal range according to anti-thyroid antibody status

Full Information

First Posted
April 7, 2017
Last Updated
March 27, 2018
Sponsor
Medstar Health Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT03115515
Brief Title
Safety and Efficacy of Empiric Levothyroxine (LT4) Dose Increase Versus Individualized LT4 Dose Increase in Hypothyroid Women During Pregnancy
Official Title
Randomized, Prospective Trial Comparing the Safety and Efficacy of Empiric Levothyroxine (LT4) Dose Increase Versus Individualized LT4 Dose Increase in Hypothyroid Women During Pregnancy
Study Type
Interventional

2. Study Status

Record Verification Date
March 2018
Overall Recruitment Status
Completed
Study Start Date
August 2011 (undefined)
Primary Completion Date
February 2018 (Actual)
Study Completion Date
February 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Medstar Health Research Institute

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
In women who require thyroid hormone replacement medication, the investigators will compare 2 ways to adjust thyroid medication during pregnancy to determine superiority in maintaining optimal blood levels of thyroid hormone. Thyroid hormone requirements increase significantly in pregnancy and it is important that blood levels of thyroid hormone remain normal so the fetus, which cannot make its own thyroid hormone has enough for early prenatal development. This trial compares 2 methods for adjusting thyroid medicine during pregnancy in women with known thyroid disease. Pregnant women (age 18 to 45) who take thyroid medication will be randomized to either 1) a 2-dose per week increase in thyroid medicine once pregnancy is confirmed, followed by dose adjustments every 2-4 weeks, or 2) adjustments in thyroid medication every 2-4 weeks in micrograms per day based on results of blood tests. The investigators will compare thyroid hormone levels throughout pregnancy between the groups of mothers to determine which method is superior in meeting the increased thyroid hormone requirements during pregnancy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pregnancy Related, Thyroid
Keywords
Thyroid Stimulating Hormone

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Adjustment in number of doses of thyroid hormone per week
Arm Type
Experimental
Arm Description
Patients in this group will increase pre-pregnancy thyroid hormone dose by 2 doses/week (extra dose on Wednesday and Saturday). Further dose adjustment are made every 2-4 weeks based on serum TSH, as shown below: TSH>10mIU/L, increase by 3 doses/week TSH 5.0-9.9mIU/L, increase by 2 doses/week TSH 2.0-4.9mIU/L, increase by 1 dose/week TSH 0.4-1.9mIU/L, no change TSH<0.4mIU/L, decrease by 1 dose/week TSH<0.1mIU/L, decrease by 2 doses/week Thyroid hormone dose will NOT be decreased due to TSH<0.4mIU/L during the 1st trimester unless patient also has elevated circulating T4 and/or T3 levels, indicate of true hyperthyroidism.
Arm Title
Adjustment in micrograms per day of thyroid hormone
Arm Type
Experimental
Arm Description
Patients in this group adjust thyroid hormone dose based on Visit 1 TSH and pre-pregnancy thyroid hormone dose. Further dose adjustments are made every 2-4 weeks based on serum TSH, as shown below: TSH>10mIU/L, increase dose by 50mcg/day if dose <125mcg/day or increase by 75mcg/day if dose >125mcg TSH 5.0-9.9mIU/L, increase dose by 25mcg/day if dose <125mcg/day or increase by 50mcg/day if dose >125mcg TSH 2.0-4.9mIU/L, increase dose by 12.5mcg/day if dose <125mcg/day or increase by 25mcg/day if dose >125mcg TSH 0.4-1.9mIU/L, no change TSH<0.4mIU/L, decrease dose by 12.5mcg/day if dose <125mcg/day or decrease by 25mcg/day if dose >125mcg/day TSH<0.1mIU/L, decrease dose by 25mcg/day if dose <125mcg/day or decrease by 50mcg/day if dose >125mcg/day Thyroid hormone dose will NOT be decreased due to TSH<0.4mIU/L during the 1st trimester unless patient also has elevated circulating T4 and/or T3 levels, indicate of true hyperthyroidism.
Intervention Type
Drug
Intervention Name(s)
levothyroxine
Other Intervention Name(s)
Synthroid, Levoxyl
Intervention Description
To compare two different methods of adjusting thyroid hormone replacement during pregnancy to maintain TSH within the normal reference range for pregnancy.
Primary Outcome Measure Information:
Title
% of TSH values within trimester-specific goal range per patient from study enrollment to delivery
Description
% of TSH values within trimester-specific goal range according to study group
Time Frame
TSH will be assessed every 2 weeks from enrollment to 28 weeks gestation and then every 4 weeks from 29 weeks to delivery
Secondary Outcome Measure Information:
Title
Mean number of LT4 dose adjustment
Description
Mean number of LT4 dose adjustments needed per patient in each group
Time Frame
Dose adjustments will be assessed every 2 weeks from enrollment to 28 weeks gestation and then every 4 weeks from 29 weeks to delivery
Title
Mean number of LT4 dose adjustments by hypothyroidism etiology
Description
Mean number of LT4 dose adjustments needed according to etiology of hypothyroidism in each group
Time Frame
Dose adjustments will be assessed every 2 weeks from enrollment to 28 weeks gestation and then every 4 weeks from 29 weeks to delivery
Title
% of TSH values at goal according to anti-thyroid antibody status
Description
TSH values within trimester specific goal range according to anti-thyroid antibody status
Time Frame
TSH will be assessed every 2 weeks from enrollment to 28 weeks gestation and then every 4 weeks from 29 weeks to delivery

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Female between ages of 18-45 who takes thyroid hormone replacement medicine AND pregnant or plan to become pregnant in the near future. Exclusion Criteria: Males Younger than 18 or older than 45 years old More than 10 weeks pregnant at enrollment Iodine deficient Pregnant with more than one baby (i.e., twins, triplets, etc.) NOT taking thyroid hormone medicine before becoming pregnant Levels of thyroid hormone in blood have been too low or too high in the past 6 months Treated with radioactive iodine in the past year.
Facility Information:
Facility Name
Medstar Washington Hospital Center
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20010
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
28911144
Citation
Sullivan SD, Downs E, Popoveniuc G, Zeymo A, Jonklaas J, Burman KD. Randomized Trial Comparing Two Algorithms for Levothyroxine Dose Adjustment in Pregnant Women With Primary Hypothyroidism. J Clin Endocrinol Metab. 2017 Sep 1;102(9):3499-3507. doi: 10.1210/jc.2017-01086.
Results Reference
derived

Learn more about this trial

Safety and Efficacy of Empiric Levothyroxine (LT4) Dose Increase Versus Individualized LT4 Dose Increase in Hypothyroid Women During Pregnancy

We'll reach out to this number within 24 hrs